A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention
of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.